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1. SUMMARY 
Our studies revealed that neural changes underlying trauma-induced PTSD-like 
behavioral deficits depend on the nature of the traumatic experience and the challenge 
subjects are exposed to during behavioral testing. Moreover, neural changes have a temporal 
evolution that is not reflected at behavioral level. This complexity mirrors the complexity of 
the human disorder and may explain why the treatment of this disorder is so difficult. Our 
findings also show that this field needs a complex, multidimensional approach; the frequently 
used 2-day long conditioned fear test is insufficient to understand the mechanisms of trauma-
induced behavioral deficits. 
As it regards the role of cannabinoid signaling in trauma-induced behavioral deficits, we 
suggest that this role can be best described in terms of coping styles. Enhanced anandamide 
(and possibly 2-AG) signaling increases the predilection of animals to adopt an active coping 
style. Basic alternative strategies by which individuals respond to environmental challenges 
(i.e. coping styles) have wide-ranging health implications from immunity to psychopathology, 
and active coping has been indicated as a therapeutic goal for psychological interventions in 
various disorders. As such, the enhancement of endocannabinoid signaling may become a 
therapeutic option in emotional disorders that are characterized changes in coping strategies 
e.g. in post-traumatic stress disorder. 
2. THE MAIN AIMS OF THE PROJECT PROPOSAL 
Our project proposal hypothesized that cannabinoid signaling is deeply involved in the 
development of post-traumatic stress disorder (PTSD), and agents acting on cannabinoid 
receptors and/or endocannabinoid metabolism constitute a novel approach to the therapy of 
PTSD. The proposal listed three main aims: (i) to evaluate the effects of cannabinoid-related 
treatments on various symptoms and models of PTSD, (ii) to understand the brain 
mechanisms underlying the effects of cannabinoids, and (iii) to compare the efficacy of 
selected cannabinoid-related treatments with the effects of conventional PTSD therapies. 
Ultimately our project aimed at understanding the pathomechanisms of PTSD, and at the 
identification of novel treatment strategies for this disorder. 
3. LIST OF STUDIES PERFORMED AND THE MAIN FINDINGS 
3.1. Mechanisms underlying behavioral deficits observed in laboratory models of PTSD 
3.1.1. The models and methodologies employed 
We proposed to study the mechanisms of PTSD-like symptoms by a multidimensional 
analysis of trauma-related deficits in laboratory models of the disorder. In line with the 
project proposal, we employed in our studies four laboratory models. In two of these models, 
traumatic experience consisted of electric shocks. In the remaining two models, traumatic 
experience was induced by predator exposure and the so-called submersion stress (experience 
of suffocation). In the case of electric shocks, the behavioral endpoints were social deficits 
and contextual conditioned fear. Social deficits were studied in two models e.g. the social 
avoidance and the psychosocial stress paradigms. The conditioned fear test was performed at 
two time-points, one and 28 days after shocks. In the case of predator exposure and 
submersion test, the behavioral effects of traumatic experience were studied by means of the 
elevated plus-maze test of anxiety. In these studies, subjects strongly affected and weakly 
affected by traumatic experience were studied separately. Trauma-induced changes in 
addiction-related behaviors were also studied. 
Neural mechanisms were studied by c-Fos immunocytochemistry. In certain studies, we 
identified the activated neurons by means of neuronal markers, while real-time PCR was used 
as a complementary method in other studies. The local brain administration of compounds 
was also employed; these studies were presented in chapter 3.2.4.  
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3.1.2 Findings 
3.1.2.1 Social deficits resulting from traumatic experience are mediated by plastic changes in 
the central and basolateral amygdala 
In our study concerning the neural mechanisms of shock-induced social deficits (Mikics 
et al., 2008), we exposed rats to a single series of electric foot-shocks ‒ a frequently used 
model of trauma ‒ and studied their behavior in the social avoidance and psychosocial 
stimulation tests (non-contact versions of the social interaction test) at different time intervals. 
Social interaction-induced neuronal activation patterns were studied in the prefrontal cortex 
(orbitofrontal and medial), amygdala (central, medial, and basolateral), dorsal raphe and locus 
coeruleus. Shock exposure markedly inhibited social behavior in both tests. The effect lasted 
at least 4 weeks, and amplified over time. As shown by c-Fos immunocytochemistry, social 
interactions activated all the investigated brain areas. Traumatic experience exacerbated this 
activation in the central and basolateral amygdala, but not in other regions. The tight 
correlation between the social deficit and amygdala activation patterns suggest that the two 
phenomena were associated. A real-time PCR study showed that CRF mRNA expression in 
the amygdala was temporarily reduced 14, but not 1 and 28 days after shock exposure. In 
contrast, amygdalar NK1 receptor mRNA expression increased throughout. Thus, the trauma-
induced social deficits appear to be associated with, and possibly caused by, plastic changes 
in fear-related amygdala subdivisions. 
3.1.2.2 Anxiety-like consequences of predator exposure are mediated by the medial amygdala 
and prefrontal cortex, whereas the behavioral consequences of submersion stress depend on 
the serotonergic cells of the dorsal raphe 
Our findings using predator exposure and submersion stress as traumatic events were 
summarized in two publications (Adamec et al., 2012a, 2012b). This study was performed in 
cooperation with the group of Robert Adamec, Canada. The effects of the two stressors were 
studied in comparison. This first study (Adamec et al., 2012a) had two purposes. First: to 
compare predator and water submersion stress cFos activation in medial prefrontal cortices 
(mPFC) and the medial amygdala (MeA). Second: to identify markers of vulnerability to 
stressors within these areas. Rats were either predator or submersion stressed and tested 1.75 
h later for anxiety. Immediately thereafter, rats were sacrificed and cFos expression was 
examined. Predator and submersion stress equally increased anxiety-like behavior in the 
elevated plus maze (EPM) and hole board. To examine vulnerability, rats which were less 
anxious (LA) and more (highly) anxious (MA) in the EPM were selected from among handled 
control and stressed animals. LA stressed rats were considered stress non-responsive while 
MA stressed rats were considered stress responsive. Predator stress, but not submersion stress, 
activated MeA cFos. CFos expression of mPFC cells was elevated in LA rats and reduced in 
MA rats in predator stressed animals only, correlating negatively with anxiety. These findings 
are consistent with data implicating greater mPFC excitability in protection against the effects 
on affect of traumatic stress. The findings also suggest that this conclusion is stressor specific, 
applying to predator stress but not submersion stress. Both stressors have been suggested to 
model hyperarousal and comorbid anxiety aspects of PTSD in humans. Hence the use of these 
paradigms to identify brain bases of vulnerability and resilience to traumatic stress in PTSD 
has translation potential. On the other hand, our evidence of stressor specificity of 
vulnerability/resilience markers raises a caution. The data suggest that preclinical markers of 
vulnerability/resilience in a given stress paradigm are at best suggestive, and translational 
value must ultimately be confirmed in humans. The second study of the same series (Adamec 
et al., 2012b) was performed under very similar conditions, but here we focused on the 
brainstem, namely on the dorsal raphe where serotonergic and non-serotonergic neurons were 
differentially studied and the locus coeruleus. LA and MA rats did not differ in cFos 
expression in any brain area, though stressors did increase cFos cell counts in all areas over 
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controls. Intriguingly, the number of serotonergic DR neurons not activated by stress 
predicted degree of anxiety response to submersion stress only. LA submersion stressed rats 
had more serotonergic cells than all other groups, and MA submersion stressed rats had fewer 
serotonergic cells than all other groups, which did not differ. Moreover, these cell counts 
correlated with EPM anxiety. We conclude that a surplus of such cells protects against 
anxiogenic effects of submersion, while a paucity of such cells enhances vulnerability to 
submersion stress. Other data suggest serotonergic cells may exert their effects via inhibition 
of dorsolateral PAG cells during submersion stress. Findings are discussed with respect to 
serotonergic transmission in vulnerability to predator stress and relevance of findings for post 
traumatic stress disorder (PTSD). This article was part of a Special Issue of 
Neuropharmacology entitled 'Post-Traumatic Stress Disorder'. 
3.1.2.3. The control of shock-induced conditioned fear undergoes rapid changes after shock 
exposure; lasting conditioned fear implicates the medial prefrontal cortex, medial and 
basolateral amygdala, anterior hypothalamic nucleus, median raphe and periaqueductal gray 
Our last study in this series (Tulogdi et al., 2012) was prompted by discrepant earlier 
findings concerning the role of various brain regions in conditioned fear. We hypothesized 
that discrepant findings were due to dynamic neural changes that followed shocks, and a more 
consistent picture would emerge if consequences were studied after a longer interval. 
Therefore, we exposed rats to a single session of footshocks and studied their behavioral and 
neural responses one and 28 days later. The neuronal activation marker c-Fos was studied in 
24 brain regions relevant for conditioned fear, e.g. in subdivisions of the prefrontal cortex, 
hippocampus, amygdala, hypothalamic defensive system, brainstem monoaminergic nuclei 
and periaqueductal gray. The intensity of conditioned fear (as shown by the duration of 
contextual freezing) was similar at the two time-points, but the associated neuronal changes 
were qualitatively different. Surprisingly, however, Multiple Regression Analyses suggested 
that conditioned fear-induced changes in neuronal activation patterns predicted the duration of 
freezing with high accuracy at both time points. We suggest that exposure to electric shocks is 
followed by a period of plasticity where the mechanisms that sustain conditioned fear undergo 
qualitative changes. Neuronal changes observed 28 days but not 1 day after shocks were 
consistent with those observed in human studies performed in PTSD patients. 
3.1.2.4. Traumatic experience induced by electric shocks durably affect behavior in tests 
relevant to drug abuse in conjunction with the development of post-traumatic stress disorder-
like behavioral dysfunctions 
In addition to the studies listed above, we also studied the impact of traumatic experience 
on addiction-related behaviors. Rats exposed to 10 shocks of 3 mA over 5 min showed a 
robust conditioned fear 28 days later, which confirms the traumatic nature of shock exposure. 
A different set of rats was studied in the conditioned place preference paradigm beginning 
with the 27th post-shock day. 10mg/kg morphine induced a marked place preference in both 
shocked and non-shocked rats. Although the magnitude of place preference was not affected, 
extinction was markedly delayed in shocked rats. We also investigated tolerance to the 
hyperthermic effects of morphine. A low dose (5mg/kg) that was administered 4 weeks after 
shock exposure robustly increased body temperature in both shocked and non-shocked rats. 
Repeated injections resulted in a mild tolerance in non-shocked controls; yet, morphine 
readily increased body temperature in these rats on the 5th day of injections. In contrast, the 
temperature-heightening effect of morphine was abolished in shocked rats after 2 days. Thus, 
shock exposure considerably delayed the extinction of place preference induced by, and 
dramatically accelerated the tolerance to the effects of, morphine. Our study shows that 
electric shocks durably affect behavior in tests relevant to drug abuse in conjunction with the 
development of post-traumatic stress disorder-like behavioral dysfunctions. This study aimed 
at describing the phenomenon, the neural background of which was planned to be studied 
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later. We discovered in the meantime that endocannabinoid signaling affects coping 
responses, which has a large impact on PTSD-like behavioral dysfunctions, for which our 
attention was shifted to this issue and the "neurochemical mechanism part" of this particular 
study was not performed. We mention that such studies were not planned. 
3.1.3 Conclusions 
We studied here the neuronal background of various trauma-induced behavioral deficits 
in four laboratory models of PTSD. Surprisingly, large differences were observed between the 
four models; moreover, the neuronal background of behavioral deficits of different nature 
(e.g. social fear vs. conditioned fear) was different even when the traumatic experience was 
similar. We also revealed that neural mechanisms undergo rapid changes after the traumatic 
experience; the very same behavioral response (e.g. freezing in shock-associated 
environments) is controlled by different mechanisms 1 and 28 days after shocks. 
The complexity of trauma-induced neural changes mirrors the complexity of the human 
disorder and may provide a hint on the reasons why the treatment of this disorder is so 
difficult. At the same time our findings demonstrate that this field needs a complex, 
multidimensional approach; the frequently used 2-day long conditioned fear test is 
insufficient to understand the mechanisms underlying trauma-induced behavioral deficits. 
3.2.Cannabinoid mechanisms underlying anxiety and PTSD-like behavioral 
dysfunctions in laboratory models 
3.2.1. Models and methodologies employed 
The main PTSD model employed in these studies was the conditioned fear paradigm. 
Consequences were studied either one or several weeks (usually 4) after electric shocks. To 
study the involvement of endocannabinoids we used CB1-KO mice, and various cannabinoid 
ligands. The main pharmacological tool employed in these studies was, however, the FAAH 
inhibitor URB597, which indirectly enhances endocannabinoid ‒particularly anandamide‒ 
signaling. Compounds were administered either systemically or locally into distinct brain 
regions. The behavioral tests used in these studies include the elevated plus-maze test of 
anxiety, the conditioned fear paradigm a laboratory model of PTSD, the forced swimming test 
of depression, and two tests of coping. Beyond behavioral methods, we also employed 
hormone measurements, in vivo biotelemetry, and electrophysiological studies to evaluate the 
short and long-term consequences of traumatic experiences. 
3.2.2. Endocannabinoid signaling and 5-HT3 receptor-mediated serotonergic 
neurotransmission interactively control anxiety and the long-term effects of traumatic 
experience 
The first series of studies focused on the interaction between cannabinoid signaling, 
serotonergic neurotransmission mediated by 5-HT3 receptors, and GABAergic mechanisms 
underlying anxiety and PTSD-like behavioral dysfunctions in mice and rats (Mikics et al., 
2009). Neuroanatomic findings revealed that CB1 cannabinoid and 5-HT3 receptors are co-
expressed by a subtype of gamma-amino butyric acid (GABA)ergic interneurons in the 
prefrontal cortex, hippocampus, and basolateral amygdala, three brain regions that are crucial 
for the control of anxiety. In these regions, serotonergic inputs increase GABA release 
through 5-HT3 receptors, the phenomenon being retrogradely controlled by cannabinoid 
neurotransmission. This suggests a functional interaction between 5-HT3 neurotransmission 
and CB1 signaling. In a first attempt to investigate the behavioral relevance of these 
interactions, we studied the effects of the selective 5-HT3 agonist 1-(m-chlorophenyl)-
biguanide (mCPBG), on plus-maze behavior in NMRI, CD1 wild type, and CB1-KO mice. 
The genetic disruption of CB1 receptors consistently increased anxiety. This effect was 
significantly decreased by the 5-HT3 agonist, mCPBG. The dose-response curve was bell-
shaped. Surprisingly, mCPBG did not affect the behavior of CD1 wild type and NMRI mice. 
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We hypothesize that in the aforementioned regions, 5-HT3 activation decreases anxiety by 
promoting GABA release, but this effect is dampened by CB1 signaling. The disruption of 
CB1 receptors in CB1-KOs released GABA neurons from retrograde inhibition and made the 
effects of 5-HT3 stimulation conspicuous. Altogether, our findings revealed a functional 
interaction between 5-HT3 neurotransmission and CB1 signaling. Besides this interaction 
being an interesting aspect of anxiety control, it may also explain the notoriously inconsistent 
effects of 5-HT3 ligands on anxiety. If 5-HT3 neurotransmission and CB1 signaling interact, 
the anxiety-related effects of 5-HT3 ligands may depend on species, strain, and situation-
related differences in both 5-HT3 and CB1 receptor expression and function.  
The same interaction was studied later in the conditioned fear paradigm, a putative 
laboratory model of PTSD (Mikics and Haller in preparation; estimated publication year: 
2013). Although the findings of this study are not fully available yet, the study clearly showed 
that similar to anxiety PTSD-like behavioral dysfunctions strongly depended on the 
interaction between endocannabinoid signaling and serotonergic mechanisms mediated by 5-
HT3 receptors. 
3.2.3. The indirect modulation of endocannabinoid signaling by the inhibition of the 
anandamide-degrading enzyme FAAH - complex and context-dependent effects on anxiety 
In an attempt to characterize more specifically the role of endocannabinoid system in 
anxiety and PTSD-like behavioral dysfunctions, we employed the FAAH inhibitor URB597 
in our studies (Scherma et al., 2008b). When the anxiety-related effects of the 
endocannabinoid anandamide and the FAAH inhibitor URB597 were evaluated in a light/dark 
box, both a low anandamide dose (0.3 mg/kg) and URB597 (0.1 and 0.3 mg/kg) produced 
anxiolytic effects when given alone, but produced anxiogenic effects when combined. A 
higher dose of anandamide (3 mg/kg) produced anxiogenic effects and depressed locomotor 
activity when given alone and these effects were potentiated after URB597 treatment.  
In another study, we demonstrated that URB597 affects anxiety in a highly context-
dependent manner (Haller et al., 2009). We found that URB597 (0.1-0.3 mg/kg) did not 
produce anxiolytic effects when the aversiveness of testing procedures was minimized by 
handling rats daily before experimentation, by habituating them to the experimental room, or 
by employing low illumination during testing. In contrast, URB597 had robust anxiolytic 
effects when the aversiveness of the testing environment was increased by eliminating 
habituation to the experimental room or by employing bright lighting conditions. Unlike 
URB597, the benzodiazepine chlordiazepoxide (5 mg/kg) had anxiolytic effects under all 
testing conditions. The anxiolytic effects of URB597 were abolished by the cannabinoid CB1-
receptor antagonist AM251, showing that they were mediated by CB1 receptors. Close 
inspection of experimental conditions employed in earlier reports suggests that conflicting 
earlier findings with URB597 can be explained by different testing conditions, such as those 
manipulated in the present study. Our findings showed that FAAH inhibition does not affect 
anxiety under mildly stressful circumstances but protects against the anxiogenic effects of 
aversive stimuli. This series of studies led us to conclude that endocannabinoid signaling 
affects in fact coping strategies and affects the development of PTSD-like behavioral 
dysfunctions via this route. Our findings related to this phenomenon will be presented below. 
3.2.4. The interaction between endocannabinoid signaling, coping with aversive stimuli, and 
long-term deficits induced by traumatic experience 
We will present the findings of this last experimental series of the project in detail, partly 
because the findings were not yet published, and partly because the findings of these studies 
represent the quintessence of the whole project, and summarize our most important finding, 
namely the impact of cannabinoids on coping styles and the relevance of this phenomenon for 
post-traumatic stress disorder. 
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3.2.4.1 Theoretical premises 
Active and passive coping are two distinct phenotypes, which differ in the way in which 
challenges are dealt with (Koolhaas et al., 1999; Koolhaas, 2008). In novel situations, active 
copers base their behavior on routines that are weakly influenced by environmental stimuli 
and attempt to control challenges when they occur. Thus, behavior is internally driven and 
problem-oriented in active copers. In contrast, passive copers are governed by environmental 
stimuli and tend to answer challenges by inactivity, demonstrating externally-driven and 
avoidant behavior. These temporally stable behavioral phenotypes were shown to have 
adaptive significance in animals, while in humans (where they are often depicted as Type "A" 
and Type "C" coping) they influence disease susceptibility and resilience under adverse 
conditions(Irvine et al., 1982; Kessler et al., 1985; Koolhaas et al., 1999; Koolhaas, 2008; 
Stewart and Yuen, 2011; Temoshok, 2000); moreover, coping styles are believed to predict 
disease-induced decreases in quality of life more accurately than disease severity (Pucheu et 
al., 2004; Westerhuis et al., 2011). Consequently, interventions promoting active coping 
styles –which are associated more favorably with resilience–, were proposed as therapeutic 
goals in a variety of severe physical and mental diseases (Cooke et al., 2007; Sawyer et al., 
2009; Tiemensma et al., 2011; Westerhuis et al., 2011). Disparate findings suggest that coping 
styles are determined at the level of the prefrontal cortex (Stalnaker et al., 2009) and are 
influenced by serotonergic neurotransmission (Wilhelm et al., 2007), but their neural 
mechanisms remain poorly understood. Endocannabinoids appeared to be good candidates for 
controlling coping responses as these signaling molecules are synthesized on demand in 
response to aversive environmental stimuli (Hohmann et al., 2005; Kirkham et al., 2002; 
Marsicano et al., 2002; Walker et al., 1999) and serve as feedback mechanisms that reduce 
challenge-induced neuronal excitations (Hohmann et al., 2005; Gerdeman and Lovinger, 
2001; Straiker and Mackie, 2009). We have recently shown within this project that 
anandamide decreases anxiety-like behavior indirectly by blunting the behavioral impact of 
aversive stimuli (Haller et al., 2009), and the same may be true for the other major 
endocannabinoid 2-arachidonoylglycerol (Sciolino et al., 2011). This suggested that 
endocannabinoids determine coping styles by influencing the impact of the environment on 
behavior. We performed a series of studies to investigate this hypothesis and to establish its 
relevance for conditioned fear a putative model of post-traumatic stress disorder. 
3.2.4.2 Findings 
FAAH inhibition promotes independence from anxiety-linked stimuli in rats 
We first tested the effects of URB597 in the elevated plus-maze model of anxiety under 
three sets of conditions. At one extreme, we studied rats under non-aversive conditions: low 
light (<5 lx) in a habituated testing environment. At the other extreme, we studied rats under 
aversive conditions: high light (>300 lx) in an unfamiliar environment. The third condition 
involved an intermediate level of aversiveness: a habituated environment but with high 
lighting. These experimental conditions elicit differential HPA-axis activation consistent with 
the intended level of aversiveness (Haller et al., 2009). In line with earlier observations, URB 
did not affect anxiety under the intermediate, mildly aversive condition (habituated 
environment, high light) but decreased anxiety under the aversive condition (Haller et al., 
2009) (Figs 1 a-c)1. But, compared to vehicle-treated rats, URB597 induced anxiety-like 
behavior when given under the least aversive conditions (habituation, low light). This 
surprising finding could lead to the conclusion that anandamide can have either anxiogenic or 
anxiolytic effects depending on environmental conditions. However, an alternative 
interpretation is suggested by the fact that the behavior of the URB597-treated rats was about 
the same under all three conditions, while the vehicle-treated rats showed anxiety-like effects 
                                               
1 Figures were presented at the end of this report 
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in the intermediate and aversive conditions (Figs 1d-f; open arm exploration dramatically 
decreased in parallel with the increase in the aversiveness). Thus, vehicle treated rats reacted 
strongly to the environment, but this reactivity was reduced and abolished in rats treated with 
0.1 and 0.3 mg/kg URB597, respectively. 
To elucidate the brain areas involved in this novel behavioral response, we delivered 
URB597 into areas known to be involved in anxiety, the medial prefrontal cortex and the 
amygdala. The prefrontal cortex was also implicated in defining coping styles (Stalnaker et 
al., 2009). The drug was delivered through chronic implants due to the aversiveness 
(handling, restraint) associated with acute local injections, which would have interfered with 
the testing conditions that were keys to these studies. When delivered into the medial 
prefrontal cortex, URB597 produced a profile of behavioral effects very similar to that seen 
after acute intraperitoneal injections (Figs 2a-c). In contrast, URB597 did not alter the 
responsiveness of rats to environmental conditions when delivered into the amygdala (Figs 
2d-f). Taken together, these findings suggest that URB597 decreased reactivity to 
environmental conditions by a mechanism involving the medial prefrontal cortex (involved in 
both anxiety and coping) but not the amygdala (involved in anxiety mainly). URB597 was 
clearly detectable at the end of the experiment in the prefrontal cortex where anandamide 
showed the expected changes (Fig. 2g). 
Anandamide-induced control over challenging situations in rats 
We studied the effects of UB597 in the tail-pinch test, where a small clamp is attached to 
rats' tails and coping styles are indicated by activity directed at removing the clamp (Giorgi et 
al., 2003). This paradigm was chosen over more widely used tests of coping because it allows 
repeated testing to detect changes in coping styles within subjects. Coping style in the tail-
pinch test was characterized by the ratio between clamp-oriented (e.g. gnawing the clamp) 
and environment-oriented (e.g. exploration) behaviors. When rats were repeatedly treated 
with vehicle, the behavioral profile of individuals was highly consistent over time, and the 
ratio clearly differentiated three types of individuals in terms of coping style: active (more 
than 60% of time spent with clamp gnawing; ratio >1.5), passive (more than 60% of time 
spent with exploration; ratio <0.66) and mixed style (0.66<ratio>1.5). 
In contrast to vehicle treatments, URB597 dose-dependently altered coping styles, such 
that behavioral differences between active, passive and mixed copers disappeared (Fig. 3a). 
Generally, URB597 shifted the passive and mixed copers towards a more active style, while 
the active copers remained active or shifted slightly toward a less active style. The 
cannabinoid CB1 receptor antagonist/inverse agonist rimonabant (at a dose that had no effect 
when given alone) abolished the effects of URB597 on coping (Fig. 3b). The frequency 
distribution of coping styles in the above two studies revealed a significant shift towards 
active coping styles after URB597 treatment (Fig. 3c), a behavioral change not secondary to 
altered sensitivity to clamp-induced discomfort, as neither coping style nor URB597 affected 
pain perception (Fig. 3d). Since the experimental situation used to assess coping was highly 
aversive and therefore conducive to URB597 having an anxiolytic effect, we also studied the 
effects of the anxiolytic benzodiazepine chlordiazepoxide; the results of this experiment led to 
the conclusion that alterations in coping styles are not a general consequence of anxiolytic 
treatments (Fig. 3e). Taken together, these findings point towards a strong involvement of 
anandamide signaling in shaping coping styles by a mechanism involving the CB1 receptor. 
Enhanced anandamide signaling by FAAH inhibition in rats eliminates differences in coping 
styles by promoting active coping overall. 
FAAH inhibition and coping in mice 
The behavioral effects of cannabinoids may depend on the relative cannabinoid 
responsiveness of GABAergic and glutamatergic neurotransmission, and marked species 
differences have been reported in this respect (Haller et al., 2007). Therefore, we employed 
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mice to investigate whether the findings obtained in rats are valid in this species. We also 
changed the experimental paradigm to check whether the impact of URB597 on stimulus 
responding is dependent on the sensory modality. Mice were studied in the forced swimming 
test of depression-like behavior under three different water temperatures. In this species, 
floating —a depression-like behavior in this test— is markedly decreased when water 
temperature is increased from the usual 20-25oC to about 35oC (Arai et al., 2000). We also 
found that mice floated significantly less in warm (35oC) than in cold water (15 or 25oC) (Fig 
4a). In addition, the corticosterone response to forced swimming was reduced, showing that 
mice felt more comfortable in warm as compared to cold water (Fig 4b). FAAH inhibition by 
URB597 did not affect behavior when mice swam at low temperature, but it increased 
floating and decreased struggling and swimming at 35oC (Figs 4c-e). It occurs, however, that 
this depression-like effect —surprising for a putative antidepressant— was secondary to 
decreased responsiveness to water temperature. While vehicle treated mice strongly 
responded to it, URB597-treated mice failed to do so (Figs 4f-h). These findings suggest that 
URB597 abolishes the behavioral consequences of comfortably warm water which mirrors 
the findings obtained in rats exposed to the elevated plus-maze under comfortable conditions. 
Encouraged by the parallelisms between rat plus-maze and mouse forced swimming 
findings, we investigated the impact of URB597 on coping in mice. We employed the back-
test that was initially developed for piglets (Ruis et al., 2001), and was later adapted to rats 
(Hawley et al., 2010) to evaluate coping styles by assessing behavioral resistance to a forced 
unnatural position. After submitting mice repeatedly to this test, we concluded that their 
behavior is consistent over time, and that coping styles are clearly separable and remain 
constant after repeated testing (Figs 5a, b). Thus, this test –like the tail-pinch test– offered the 
advantage of following alterations in coping in the very same animals. In a second 
experiment, coping styles again remained constant when tests were preceded by vehicle 
treatment (Fig 5c). In contrast, FAAH inhibition by URB597 promoted active coping in mice 
that showed passive coping during the vehicle trial (Fig 5d). 
The emotional impact of shock reminders - the role of endocannabinoid signaling 
It has been postulated that behavioral/emotional vulnerability to excessively strong 
(traumatic) stressors are strongly modulated by coping styles. Particularly, coping with a 
severe stressor has an impact on both the development of post-traumatic disorder (PTSD) in 
humans (Yehuda et al., 2006; Gil and Caspi, 2006) and the development of PTSD-like 
behavioral dysfunctions in laboratory models (Walker et al., 2008). Prompted by these earlier 
findings, we hypothesized that FAAH inhibition would ameliorate the behavioral and 
emotional impact of traumatic stressors by interacting with coping styles. Therefore, we 
investigated the effects of URB597 in the shock-induced contextual conditioned fear 
paradigm, a model frequently used to model PTSD and to study its neurobehavioral 
mechanisms in the laboratory (Ciocchi et al., 2010). Treatment with URB597 was given only 
once, 40 min before the conditioning phase (i.e. before shocks). Each shock elicited runs of 
about 50 cm and occasional escape jumps that were not affected by URB597 treatment (Fig 
6a). This shows that in line with the data in rats (Fig 3d) pain sensitivity was not affected by 
this compound. However, FAAH inhibition significantly affected the behavior observed 
between shock presentations. That is, locomotion during the 30-s breaks that separated shocks 
was gradually reduced from about 10 cm to almost nil in vehicle-treated mice, but there were 
two waves of locomotion bouts in URB597-treated mice, resulting in an overall increase in 
locomotion (Fig 6b). Interestingly, the direction of exploration was also changed. While 
vehicle-treated mice directed their exploratory activity mostly in the air, URB597-treated 
mice spent an equal amount of time exploring the space between and beneath the metallic grid 
by which shocks were delivered (Fig 6c). Freezing was also reduced by FAAH inhibition (Fig 
5d). Overall, our findings show that the behavioral inhibition induced by shocks was 
You created this PDF from an application that is not licensed to print to novaPDF printer (http://www.novapdf.com)
 11 
considerably ameliorated by URB597. Thus, FAAH inhibition resulted in a more active way 
of coping with this demanding situation.  
Mice that were exposed to shocks under the influence of URB597 showed slightly but 
significantly reduced freezing when re-exposed to the shocking cage two weeks later (Fig 6d). 
Notably, mice received no treatment at this time-point. Sleep was investigated by 
electroencephalographic analysis to assess the emotional impact of shock and contextual 
reminders as it was shown that both inescapable shocks and contextual reminders increase 
wakefulness and produce fragmented sleep (Philbert et al., 2011; Sanford et al., 2003). 
Surprisingly, the impact of shocks on sleep was not particularly strong: during the 30 min that 
followed shock exposure, 20-30% of the time was already spent sleeping, and pre-shock 
levels of 80% were resumed within about 90 min (Fig 6e). In contrast, sleep was almost 
completely abolished during the 30 min that followed the contextual reminder, despite the fact 
that no shocks were delivered this time. At the end of the investigated period, control mice 
slept significantly more after the reminder than after the shock, a possible rebound effect. No 
similar changes were noticed in the group treated with URB597, where wakefulness elicited 
by the shock and by the reminder were similar (Fig. 6e). Shock exposure also resulted in 
fragmented sleep that lasted about 120 min as shown by the number of awakenings, which 
increased despite a substantial decrease in sleep duration (Fig. 6f). The contextual reminder 
did not change this pattern in mice treated with vehicle before shock presentation (i.e. 14 days 
earlier). In contrast, mice submitted to shocks concurrently with FAAH inhibition showed 
robust sleep fragmentation after shocks but not after the contextual reminder, demonstrating a 
marked decrease in the emotional impact of the reminder. Taken together, these findings 
show that FAAH inhibition during shock exposure lessened the immediate behavioral 
suppressive effects of electric shocks, and this single treatment also ameliorated the long-term 
behavioral and emotional disturbances resulting from shock exposure. 
3.2.4.3 Conclusions 
Endocannabinoids affect the function of many neurotransmitter systems, and these 
systems sometimes play opposing roles. This inherently leads to complex and situation-
dependent effects (Fride et al., 2005; Zanettini et al., 2011). Accumulating evidence suggests 
that the role of cannabinoid signaling may be general rather than linked to specific behaviors. 
For example, it has recently been proposed that cannabinoid signaling promotes emotional 
homeostasis (Marco and Viveros, 2009) and works as an emotional buffer system that ensures 
an appropriate reaction to stressful events (Ruehle et al., 2011). The findings resulting from 
this project suggest that these general roles can be best described in terms of coping styles, 
which explains contrasting findings and unifies earlier concepts. Enhanced anandamide (and 
possibly 2-AG (Sciolino et al., 2011) signaling promotes both intrinsically driven behaviors 
that buffer the impact of environmental stimuli and attempts to control challenging situations 
(i.e. it increases the predilection of animals to adopt an active coping style). Moreover, one 
can bridge the basic mechanism of action of cannabinoids (the blunting of excessive neuronal 
activation (Wilson and Nicoll, 2001) and the preferential location of CB1 receptors in the 
limbic system (Herkenham et al., 1990), and hypothesize that the main role of cannabinoid 
signaling is to blunt environmentally-induced neuronal activations, and consequently to 
increase the relative weight of intrinsic controlling mechanisms and produce a more active 
coping style. This hypothesis may shed new light on the clinical prospects of agents that 
indirectly increase endocannabinoid signaling. Basic alternative strategies by which 
individuals respond to environmental challenges (i.e. coping styles) have wide-ranging health 
implications from immunity to psychopathology(Irvine et al., 1982; Kessler et al., 1985; 
Koolhaas et al., 1999; Koolhaas, 2008; Stewart and Yuen, 2011; Temoshok, 2000). In fact, 
promoting active coping has been indicated as a therapeutic goal for psychological 
interventions in various disorders (Cooke et al., 2007; Sawyer et al., 2009; Tiemensma et al., 
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2011; Westerhuis et al., 2011). As such, the enhancement of endocannabinoid signaling may 
become a therapeutic option in emotional disorders that are characterized by excessive 
responses to environmental signals. 
3.3. Other findings and results of the project 
While performing the undertaken tasks, we carried out a series of experiments that were 
aimed at preparing certain phases or tasks of the project. Although the findings of these 
experiments were not always useful from the point of view of the main aims, they still 
provided interesting findings and as such were published. Importantly, several of these studies 
became starting points of new projects. 
3.3.1. The NR2B NMDA receptor subunit as a novel treatment approach for PTSD 
While studying the neural background of trauma-like behavioral deficits, we realized that 
NR2B subunit-expressing NMDA receptors may be involved in the behavioral deficits that 
result from traumatic experience. Earlier studies showed that NR2B blockers inhibit the 
acquisition of conditioned fear a frequently used model of post-traumatic stress disorder, but 
their effects on the expression of conditioned fear was poorly studied. We investigated in this 
experiment the effects of the selective serotonin reuptake blocker, fluoxetine, the NMDA 
blocker, MK-801, and the NR2B subunit blocker, Ro25-6981 on the expression of 
conditioned fear. Rats received 10 foot shocks administered over 5 min and were tested 24 h 
later in the shocking context. Treatments were administered 1 h before testing. Shocks 
dramatically increased freezing and reduced exploration. MK-801 and Ro25-6981 
significantly ameliorated both changes. The effects of fluoxetine were less pronounced. In the 
open field, MK-801 increased locomotion, ataxia, and stereotypy (effects typical of NMDA 
blockade). Neither fluoxetine nor Ro25-6981 affected locomotion in the open field. Thus, the 
NR2B-specific NMDA blockade preserved the beneficial effects of general NMDA 
antagonists on the expression of conditioned fear but did not produce the locomotor side-
effects typical of the latter. These findings warrant further studies on the effects of NR2B 
antagonists in models of post-traumatic stress disorder. 
3.3.2. The distribution of cannabinoid ligands after intraperitoneal injections 
The brain levels of cannabinoids that are reached after systemic administration are 
virtually unknown. To investigate this issue, we injected intraperitoneally (3)H-labeled WIN-
55,212 and SR141716A (0.3, 1 and 3 mg/kg) and estimated their accumulation in the blood, 
adipose tissue and brain. Accumulation was dose-dependent. The largest amounts were found 
in the adipose tissue, while the levels seen in the blood and brain were approximately similar. 
The accumulation of SR141716A was markedly more pronounced than that of WIN-55,212 in 
all three tissues. The brain distribution of WIN-55,212 showed large regional differences. 
Such differences were significant but much smaller with SR141716A. The largest brain levels 
noticed after intraperitoneal injections did not exceed 2.5 nmol/g. This is larger than the brain 
level of the endocannabinoid anandamide but smaller than that of 2-arachidonoyl glycerol. 
Yet, the CB1 receptor affinity of WIN-55,212 and SR-141716A is two orders of magnitude 
larger than that of 2-arachidonoyl glycerol, suggesting that the exogenously administered 
compounds were functionally more active. Our findings also suggest that brain infusion and 
in vitro techniques employing considerably larger doses than 2.5 nmol should be dealt with 
caution. It appears that measuring brain levels after systemic injections increases our 
understanding of cannabinoid effects, and provides important clues for the comparison of 
results obtained with different methodologies. 
3.3.3. The role of cannabinoids in addiction-related behaviors 
We showed that traumatic experience induced by electric shocks durably affects behavior 
in tests relevant to drug abuse in conjunction with the development of post-traumatic stress 
disorder-like behavioral dysfunctions (see Chapter 3.1.2.4). The neural background of this 
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trauma-related behavioral change was not studied. However, another study of ours performed 
in cooperation with the group of Steve R. Goldberg (Baltimore, USA) did investigate the 
interaction between addiction-related behaviors and cannabinoid mechanisms (Scherma et al., 
2008a). In these studies, we employed the fatty acid amide hydrolase (FAAH) inhibitor 
URB597 that alters endocannabinoid activity in a more functional and specific way. The 
inhibition of FAAH magnifies and prolongs the effects of the endocannabinoid anandamide 
only when and where it is synthesized and released on demand. In this study, we combined 
behavioral and neurochemical approaches to evaluate whether the FAAH inhibitor URB597 
(cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester) could alter the abuse-related effects of 
nicotine in rats. We found that URB597, at a dose (0.3 mg/kg) that had no behavioral effects 
by itself, prevented development of nicotine-induced conditioned place preference (CPP) and 
acquisition of nicotine self-administration. URB597 also reduced nicotine-induced 
reinstatement in both CPP and self-administration models of relapse. Furthermore, in vivo 
microdialysis showed that URB597 reduced nicotine-induced dopamine elevations in the 
nucleus accumbens shell, the terminal area of the brain's mesolimbic reward system. These 
findings suggest that FAAH inhibition can counteract the addictive properties of nicotine and 
that FAAH may serve as a new target for development of medications for treatment of 
tobacco dependence. 
3.3.4. Social defeat as a new model of social phobia 
We intended to use social defeat as a traumatic stressor in this project. The studies that 
aimed at developing this paradigm were not successful (i.e. repeated social defeat did not lead 
to PTSD-like behavioral dysfunctions), but interesting behavioral changes were noticed. In 
these studies, we repeatedly exposed rats to predictable or unpredictable psychosocial stress 
for 5 or 12 days and examined their anxiety in two markedly different contexts: the elevated 
plus maze and social interaction tests. Psychosocial stress and the social interaction test were 
administered under highly similar conditions, i.e. the two situations were homotypic. 
Psychosocial stress did not affect anxiety in the elevated plus-maze under any condition, but 
markedly increased anxiety in the social interaction test. In contrast, repeated restraint-a non-
social stressor heterotypic to both the elevated plus maze and social interaction tests-increased 
plus-maze anxiety, demonstrating that anxiety in this test was sensitive to repeated restraint, 
and the effects were manifested in heterotypic situations. Thus, the anxiety-related effects of 
chronic psychosocial stress-unlike those of the chronic non-social stressor-were context-
dependent. This is reminiscent of phobic anxiety, which manifests in specific situations only. 
In addition, behavior in the social interaction test showed changes that went beyond simple 
anxiogenesis. Socially stressed rats spent nearly 40% of total time in aggressive interactions. 
Based on recent data showing that social phobics are prone to violence under social pressure, 
and also based on the situation-dependent effects of the social stressor, we suggest that 
chronic psychosocial stress leads to a behavioral profile akin to social phobia. 
3.3.5. The effects of the monoacylglicerol lipase inhibitor JZL184 in tests of anxiety 
While performing the studies described above, a new compound became available 
namely the monoacylglicerol lipase inhibitor JZL184. Mirroring the effects of the FAAH 
inhibitor URB597 on brain anandamide levels, this compound enhances indirectly the brain 
levels of 2-arachidonoylglycerol, the other major endocannabinoid. We performed a study 
with this compound focusing on its anxiety-related effects (Alicki et al., 2012). The first 
studies with the monoacylglycerol lipase blocker JZL184 ‒which were performed by those 
who developed the compound‒ suggested that enhanced 2-arachidonoylglycerol signaling 
suppresses locomotion, lowers body temperature and decreases anxiety. Although the 
neurochemical effects of JZL184 develop within 30 min, its behavioral and autonomic effects 
were studied much later. To clarify temporal dynamics, we studied the effects of 
intraperitoneal JZL184 injections in mice on home-cage locomotion and body temperature for 
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120 min by in vivo biotelemetry. We also studied the effects of 4, 8 and 16 mg/kg JZL184 in 
the open-field and elevated plus-maze at various time points. In the home-cage, JZL184 
blunted injection-induced body temperature increases but had no long-term effects. Vehicle 
injections increased the duration of rapid movements while the duration of motionless periods 
was decreased, a pattern also abolished by JZL184. Although the highest dose had a mild 
long-term effect on the relative duration of motionless periods, JZL184 seemed to have phasic 
rather than tonic effects in the home-cage. By contrast, open-field and plus-maze behavior 
was affected 80 and 120 but not 40 min after treatments, which may indicate tonic rather than 
phasic effects in these tests. Our findings confirm earlier reports on the mild anxiolytic effect 
of JZL184 but surprisingly, the compound dramatically and dose-dependently increased 
locomotion in the open-field in both CD1 and C57BL/6J mice. These findings are difficult to 
reconcile at present but suggest that the effects of MAGL inhibition are more complex than 
previously thought and may strongly depend on yet unidentified factors including 
environmental conditions, the leg time of testing, species/strains, etc. 
3.3.6. Reviews 
We contributed to one review summarizing the available information on the impact of the 
endocannabinoid system on memory and emotions (including its role in PTSD-like behavioral 
dysfunctions) (Zanettini et al., 2011), and wrote a review on laboratory models of anxiety, 
including models of PTSD (Haller and Aliczki, 2012). We incorporated in these reviews the 
findings and conclusions of the project reported here. 
4. NEW PROJECTS EMERGING FROM THE ONE REPORTED HERE 
The findings end experience accumulated during the execution of this project were used 
in two successful (granted) project proposals as follows: 
(1) The European Research Council Advanced Grant entitled "Modulation of cortical 
activity by median raphe neuronal assemblies with identified behavioural effects" (Acronym: 
SERRACO). The principal investigator of this project is Tamás F. Freund; co-investigators 
are József Haller and Beáta Sperlágh. One of the important goals of the project is the study of 
the median raphe-cortical mechanisms that are involved in the control of PTSD-like 
behavioral dysfunctions. 
(2) The OTKA project 101645 entitled "Trauma-induced behavioral deficits: the role of 
NMDA and AMPA receptor subtypes" ("Traumás élmény által előidézett magatartási 
zavarok: az NMDA és AMPA receptor altípusok szerepe"). This project derived from the 
studies presented in chapter 3.3.1. 
In addition to these two projects, we intend to submit next year a project proposal for the 
study of the behavioral effects of the monoacylglicerol lipase inhibitor JZL184. This proposal 
will be based on the findings summarized in chapter 3.3.5 and additional findings obtained 
within the framework of other projects. 
5. EXPLOITATION 
Our findings suggest that the enhancement of endocannabinoid signaling by the blockade 
of degrading enzymes may become a treatment option for emotional disorders and possibly 
for the treatment of post-traumatic stress disorder.  
We believe that the interaction between endocannabinoid signaling and 5-HT3 receptor-
mediated serotonergic neurotransmission ‒as revealed by our studies ‒deserves further studies 
as it regards its therapeutic potential in emotional disorders. 
Another important finding is that the blockade of NRB2 subunit-containing NMDA 
receptors decreases conditioned fear a putative laboratory model of post-traumatic stress 
disorder. 
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Figure 1. FAAH inhibition by URB597 eliminates the impact of light and 
habituation on plus-maze behavior in rats. a-c, closed arm entries, relative open arm 
entries (open/ total arm entries) and time spent in open arms, respectively, in treatment groups 
exposed to the elevated plus-maze under different conditions d-e, Changes from the low 
light/habituation (L-h) condition that visualize the dependence of behavior from testing 
conditions. Closed arm entries were significantly affected by condition only (Fcondition(2,110)= 
12.95; P< 0.0001), while the interaction between factors was significant for both the duration, 
and the relative frequency of open arm visits (Ftreatment x condition(4,110) was 3.71 (P< 0.01) and 
3.59 (P< 0.01), respectively). Grey rectangles in d-e, s.e.m. range under L-h condition; * and 
#, significant effect of URB597 and condition, respectively (P< 0.05). Statistics was made on 
raw data; figures d-e were composed for clarity. Here and in all figures, error bars represent 
s.e.m.; P values underwent Bonferoni correction. 
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Figure 2. URB597 implanted into the prefrontal cortex but not the amygdala 
abolishes the effects of testing conditions in the rat elevated plus-maze. a, the location 
of URB597-containing cannullas in the prefrontal cortex. b and c, effects of prefrontal 
implants on anxiety-like behavior shown as in Fig. 1 a-c and d-e. d, the location of 
URB597-containing cannullas in the amygdala. e and f, effects of amygdala implants on 
anxiety-like behavior shown as indicated above. g, the concentration of URB597 and 
anandamide in the prefrontal cortex in sham and URB597-implanted rats, respectively. 2-
archidonoil glycerol showed non-significant variation (data not shown). The effects of 
prefrontal implants replicated those seen after systemic injections (Ftreatment x condition(1,25)= 
15.02 (P< 0.0001). Only the effect of condition was significant in the amygdala 
Fcondition(1,42)= 26.33 (P< 0.0001). L-h, low light/habituation condition used as baseline; 
grey rectangles in c and f, s.e.m. range under L-h condition; * and #, significant effect of 
URB597 and condition, respectively (P< 0.05). Statistics was made on raw data; figures c 
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Figure 3. FAAH inhibition promotes active coping in the rat tail-pinch test. a, The effects 0.0 (vehicle), 0.1 and 0.3 mg/kg of URB597 
on the gnawing at clamp / clamp-independent exploration ratio shown for rats showing active, mixed and passive coping styles (for further 
details see text and Supplementary data) (Fstrategy x treatment (2,70)= 8.00; p< 0.0001). b, The effects of URB597 on coping styles were abolished by 
the CB1 receptor antagonist rimonabant at a dose that did not affect coping styles per se (Fstrategy x treatment (2,68)= 5.68; p< 0.01); c, the 
distribution of strategies after vehicle and URB597 3 mg/kg treatment (Chi-Square= 11.16; p= 0.048). d, The impact of coping styles and 
URB597 on pain thresholds in the hot plate test (F(2,37)= 0.92; p> 0.4 and F(1,18)= 0.26; p> 0.6, respectively). e, The anxiolytic 
chlordiazepoxide did not close up the gap between active and passive coping. Dotted lines, gnawing/exploration ratios that delimited active, 
mixed, and passive coping styles; Veh, vehicle; Rim, rimonabant; CDP, chlordiazepoxide; *, significant differences in frequency distribution; ‡, 
all three coping styles differ significantly (P< 0.05); †, active and passive copers show significant differences; ns, no significant differences 
between coping styles. 
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Figure 4. URB597 abolishes the behavioral effects of warm water in the mouse 
forced swimming test. a, CD1 mice float less (F(2,27)= 30.16; p< 0.0001) and b, show 
lower plasma corticosterone levels in warm as compared to cold water (F2,32)= 4.54; p< 
0.02). c-e, URB597 did not affect behavior at 25 oC, but increases depression-like 
behavior at 35 oC (Fwater temperature x treatment= 4.11; p< 0.03). Data obtained at 15oC were 
similar to those obtained at 25oC (see Supplementary data). f-h, the depression-like effect 
of URB597 appears to be secondary to an abolished responsiveness to water temperature. 
Grey rectangles in f-h, s.e.m. range at 25 oC; †, significant effect of water temperature; * 
and #, significant effect of URB597 and water temperature, respectively (P< 0.05). 
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Figure 5. FAAH inhibition closes up the gap between passive and active coping in the 
mouse back test. a, three-dimensional correlation plot of escape attempts shown in three 
tests performed at 3 day intervals after vehicle treatments (Spearman R> 0.6; p< 0.01 at 
least). b, Coping styles observed on the first day remained stable over time in two 
additional testing days (Fcoping style (2,30)= 16.87; p< 0.001; no significant effects of trial 
and no interaction between factors). c and d, The effects of vehicle and URB597 
treatments in a different study. Vehicle treatments did not change coping styles. In 
contrast, passive animals adopted an active strategy after URB597 (Ftreatment*coping(2,32)= 




















































































































Figure 6. Ameliorative effects of URB597 on the immediate and delayed behavioral effects of electric shocks. The immediate effects 
of shocks on a, "shock-runs" (rapid locomotion directly elicited by shocks) (Ftreatment(1,12)= 0.15; p< 0.2), b, locomotion during the 30 s-long 
brakes that separated shocks (Ftreatment(1,12)= 7.07; p< 0.03), and c, the direction of exploratory behavior (Ftreatment(1,12)= 6.91; p< 0.03). d, 
freezing was significantly affected by treatment (F(1,12)= 5.55; p< 0.04) but not by the context (shock or reminder). Dashed columns; freezing 
shown on days 1 and 14 by treatment groups; closed columns, the average of treatment groups. e, the duration of sleep (Ftreatment*timepoint(21,168)= 
1.98; p< 0.01). f, the number of awakenings (Ftreatment(3,24)= 6.15; p< 0.003; Ftimepoint(7,168)= 18.34; p< 0.0001; Ftreatment*timepoint(21,168)= 0.95; 
p< 0.5). Colored rectangles on graphs e and f, the s.e.m. range of baselines; *, significant effect of URB597 (P< 0.05); #, significant difference 
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